GU Li, ZHANG Jun, SU Yan. Advances in the Research of Human Prolactin Receptor Antagonists G129R-hPRL in Breast Cancer Therapy[J]. Chinese Journal of Modern Applied Pharmacy, 2011, 28(1): 30-34.
    Citation: GU Li, ZHANG Jun, SU Yan. Advances in the Research of Human Prolactin Receptor Antagonists G129R-hPRL in Breast Cancer Therapy[J]. Chinese Journal of Modern Applied Pharmacy, 2011, 28(1): 30-34.

    Advances in the Research of Human Prolactin Receptor Antagonists G129R-hPRL in Breast Cancer Therapy

    • OBJECTIVE To introduce the progress of specific human prolactin receptor antagonist G129R-hPRL in breast cancer therapy research. METHODS Review the function, mechanism, advantages and disadvantages, improvements, the application and the prospect of the prolactin receptor antagonist G129R-hPRL in therapy of breast tumor through searching and summarizing relevant literatures. RESULTS G129R-hPRL can inhibit proliferation, mediate apoptosis of breast cancer cell and play the role of anti-breast cancer by competitively antagonize endogenous prolactin. G129R-hPRL-based multi-functional fusion protein, as well as combination G129R-hPRL with other anti-tumor component also shows a stronger tumor suppressor effect. CONCLUSION G129R-hPRL is expected to be an ideal drug in treatment and prevention of breast cancer.
    • loading

    Catalog

      Turn off MathJax
      Article Contents

      /

      DownLoad:  Full-Size Img  PowerPoint
      Return
      Return